Evidence map›Paper›PMID 19051060›Full record

ArticlePathology oncology research : POR2009

Contribution of XPD (Lys751Gln) and XRCC1 (Arg399Gln) polymorphisms in familial and sporadic breast cancer predisposition and survival: an Indian report.

Volga S Syamala, Vani Syamala, Hariharan Sreedharan, Praveenkumar B Raveendran, Ratheesan Kuttan, Ravindran Ankathil

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 21 citations in OpenAlex.

  1. XPD Asp312Asn and Lys751Gln polymorphisms and breast cancer susceptibility: a meta-analysis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014
    Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Genetic polymorphisms associated with breast cancer in malaysian cohort.Indian journal of clinical biochemistry : IJCB · 2015
    Article
  7. XRCC1 Arg399Gln polymorphism is not associated with breast cancer in Chinese.International journal of clinical and experimental medicine · 2015
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Volga S SyamalaDivision of Cancer Research, Regional Cancer Centre, Trivandrum, 695 011, Kerala, India.
Vani Syamala
Hariharan Sreedharan
Praveenkumar B Raveendran
Ratheesan Kuttan
Ravindran Ankathil
Regional Cancer Center, Thiruvananthapuram · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The etiology of a significant proportion of familial breast cancers is still poorly understood, with known high penetrance gene mutations accounting for only a small proportion of the cases. The increased risk of breast cancer for the majority of women with a family history likely reflects shared minor low penetrant genetic factors. In the present case-control study undertaken to examine the influence of DNA damage repair gene polymorphisms in familial and sporadic breast cancer susceptibility, 219 Sporadic and 140 familial breast cancer patients and 367 controls were genotyped using PCRRFLP. Odds Ratios (ORs) and 95% Confidence Intervals (95%CIs) were calculated by unconditional logistic regression adjusted to age. Variant genotypes XRCC1 Arg/Gln or Gln/Gln and XPD Lys/Gln or Gln/Gln increased both familial and sporadic breast cancer susceptibility. However, when the intra group risk was compared, the risk due to the XPD polymorphic genotypes Lys/Gln or Gln/Gln was significantly lower among familial breast cancer patients compared to sporadic breast cancer patients [OR = 0.61; 95%CI = 0.39-0.94; p value = 0.024) whereas the risk implied by XRCC1 variant genotype was not significantly different between the familial and nonfamilial groups of breast cancer patients [OR = 0.97; 95%CI = 0.63-1.49; p value = 0.882]. Both these variant genotypes were not associated with the disease characteristics or survival of either familial or sporadic breast cancer patients. This study represents an addition to previous published work on GSTs from the same study population and substantiates the hypothesis that the impact of the low penetrance gene polymorphisms differ by family history of the disease.

Indexed as

Polymorphism, Single NucleotideAdultBreast NeoplasmsCase-Control StudiesDNA-Binding ProteinsFemaleGenetic Predisposition to DiseaseGenotypeHumansIndiaKaplan-Meier EstimateMiddle AgedNeoplasm StagingPolymorphism, Restriction Fragment LengthXeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1DNA-Binding ProteinsERCC2 protein, humanXeroderma Pigmentosum Group D ProteinX-ray Repair Cross Complementing Protein 1XRCC1 protein, human

Identifiers

PMID19051060
OpenAlexW2051290209

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.